Stockreport

TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

TRACON Pharmaceuticals, Inc.  (TCON) 
Last tracon pharmaceuticals, inc. earnings: 2/27 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: traconpharma.com
PDF The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and d [Read more]